Market closedNon-fractional
BioVie/BIVI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About BioVie
BioVie Inc is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
Ticker
BIVI
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Carson City, United States
Employees
18
Website
bioviepharma.com
BioVie Metrics
BasicAdvanced
$25M
Market cap
-
P/E ratio
-$0.95
EPS
1.22
Beta
-
Dividend rate
Price and volume
Market cap
$25M
Beta
1.22
Financial strength
Current ratio
2.447
Quick ratio
2.432
Long term debt to equity
1.936
Total debt to equity
44.471
Interest coverage (TTM)
-10.77%
Management effectiveness
Return on assets (TTM)
-62.32%
Return on equity (TTM)
-178.58%
Valuation
Price to book
1.32
Price to tangible book (TTM)
1.38
Price to free cash flow (TTM)
-0.453
Growth
Earnings per share change (TTM)
-42.75%
3-year earnings per share growth
-49.32%
What the Analysts think about BioVie
Analyst Ratings
Majority rating from 1 analysts.
BioVie Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$0
NaN%
Net income
-$8M
-4.76%
Profit margin
0.00%
NaN%
BioVie Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q3 24
Actual
-
Expected
-$0.33
Surprise
-
BioVie News
AllArticlesVideos
BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Accesswire·1 day ago
BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Accesswire·2 weeks ago
BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD Congress
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioVie stock?
BioVie (BIVI) has a market cap of $25M as of July 06, 2024.
What is the P/E ratio for BioVie stock?
The price to earnings (P/E) ratio for BioVie (BIVI) stock is 0 as of July 06, 2024.
Does BioVie stock pay dividends?
No, BioVie (BIVI) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next BioVie dividend payment date?
BioVie (BIVI) stock does not pay dividends to its shareholders.
What is the beta indicator for BioVie?
BioVie (BIVI) has a beta rating of 1.22. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell BioVie stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.